Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Radiopharm Theranostics completes A$70 million placement

Tuesday, June 25, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has successfully completed a A$70 million placement to support its ongoing clinical programs. The company has received positive updates across four clinical programs, including the initiation of a Phase I therapeutic study targeting B7H3 with its product BetaBart (RV-01). This funding will help advance their research and development efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful completion of A$70 million placement.
  • Positive clinical updates across multiple programs.
  • IND approval from US FDA for Phase I study.

Full Press Release Details

• Announcements
• Price Sensitive
• June 25, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• August 28, 2024
• Announcements
• December 18, 2024
• Analyst Reports
• November 3, 2025
• Announcements
• September 30, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the amount raised in the placement?

Radiopharm Theranostics completed a placement of A$70 million.

What is the purpose of the placement?

The funds will support ongoing clinical programs at Radiopharm Theranostics.

What clinical study is Radiopharm initiating?

They are initiating a Phase I therapeutic study targeting B7H3 with BetaBart (RV-01).

What updates have been provided by Radiopharm?

Radiopharm has shared positive updates across four clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics A$70 million BetaBart Phase I study B7H3
Last updated: Jun 25, 2024